SCHEDULE: Coastlands Capital Discloses 5.98% Stake in Whitehawk Therapeutics

Coastlands Capital LP and its affiliates have reported a 5.98% beneficial ownership stake in Whitehawk Therapeutics, Inc. common stock.

Summary

• Coastlands Capital LP, along with its affiliates Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC, and Matthew D. Perry, collectively reported beneficial ownership of 2,819,215 shares of Whitehawk Therapeutics, Inc. common stock.
• This ownership represents 5.98% of the company's outstanding common stock.
• The percentage is calculated based on 47,128,362 shares of Common Stock outstanding as of August 4, 2025, as reported in Whitehawk Therapeutics' Form 10-Q for the quarter ended June 30, 2025.
• The filing is a Schedule 13G, filed under Rule 13d-1(b), indicating that Coastlands Capital LP, an investment adviser, and its affiliates acquired the shares in the ordinary course of business and do not intend to influence control of Whitehawk Therapeutics, Inc.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing is a factual disclosure of ownership, which is inherently neutral. However, the emergence of a new significant institutional investor can be perceived as a positive signal by the market, indicating confidence in the issuer, hence a slightly elevated score.

Positives

• A significant institutional investor, Coastlands Capital, has taken a substantial stake in Whitehawk Therapeutics, potentially signaling confidence in the company's future prospects.

Risks

• The reporting persons explicitly state that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Whitehawk Therapeutics, Inc., which addresses potential concerns about activist investor involvement.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding Whitehawk Therapeutics' operational or financial performance.

Industry Context

The disclosure of a new significant shareholder like Coastlands Capital in a biotechnology or pharmaceutical company such as Whitehawk Therapeutics can sometimes be interpreted by the market as a vote of confidence, potentially attracting further investor interest, especially if the investor has a strong track record in the sector.

Stakeholder Impact

• Shareholders: Existing shareholders may view the entry of a new significant institutional investor as a positive development, potentially increasing market confidence and liquidity.
• Management: Management of Whitehawk Therapeutics will be aware of a new substantial shareholder, though the filing explicitly disclaims intent to influence control.

Key Dates

Keywords

Whitehawk Therapeutics, Coastlands Capital, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investor, Equity Stake